ASRM Announces Historic $5 Million Endowment from Ferring Pharmaceuticals
“Transformational” Gift will Establish the “Ferring Endowment for the Education of Healthcare Professionals in Training” Washington, DC and Parsippany, NJ…
-
-
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
Analysis looks at early experience with REBYOTA in clinical practice Additional analyses evaluate efficacy and safety of REBYOTA in patients…
-
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal…
-
Ferring Named in Fortune’s 2023 Change the World List
Fortune’s “Change the World” List recognises companies that have had a positive social impact through activities that are part of…
-
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota,…
-
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the…
-
Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on…
-
Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology
Integrated analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic and includes safety data for up…
-
Ferring Pharmaceuticals on Track to Deliver ADSTILADRIN® (nadofaragene firadenovec-vncg) to Patients in Early Experience Program in September 2023
Parsippany, NJ – June 26, 2023 – Ferring Pharmaceuticals today announced it will make the intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) available…
-
Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
Approval of Prior-Approval Supplement will help to ensure the future, long-term supply and clinical activities for Ferring’s novel intravesical gene…